Dramatic response to alectinib in a patient of ALK-rearranged lung cancer with poor performance status
详细信息 查看全文
- 作者：Hisashi Tanaka ; Kageaki Taima ; Takeshi Morimoto ; Kunihiko Nakamura…
- 关键词：Lung cancer ; Alectinib ; Poor performance status ; ALK
- 刊名：BMC Research Notes
- 出版年：2016
- 出版时间：December 2016
- 年：2016
- 卷：9
- 期：1
- 全文大小：996 KB
- 刊物主题：Biomedicine general; Medicine/Public Health, general; Life Sciences, general;
- 出版者：BioMed Central
- ISSN：1756-0500
文摘
Background Lung cancers with anaplastic lymphoma kinase rearrangements are highly sensitive to anaplastic lymphoma kinase tyrosine kinase inhibition, underscoring the notion that such cancers are addicted to anaplastic lymphoma kinase activity. Several anaplastic lymphoma kinase inhibitors have been identified and are being evaluated in clinical trials. However patients with poor performance status (3 or 4) were not involved in these clinical trials, it has been unclear to use anaplastic lymphoma kinase–tyrosine kinase inhibitors for these patients. Here, we report an anaplastic lymphoma kinase-positive non small cell lung cancer patient with performance status 4, who was successfully treated with alectinib.